Extending The Life Of An Appetite-Suppressing Peptide
Main Category: Obesity / Weight Loss / FitnessAlso Included In: Biology / Biochemistry; Neurology / Neuroscience
Article Date: 21 Jul 2009 - 5:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
1 (1 votes) |
| Article Opinions: | 1 posts |
The peptide alpha-MSH works in a region of the brain known as the hypothalamus to suppress appetite. A team of researchers, at Yale University School of Medicine, New Haven, and the University of California Davis, has provided new insight into the way in which levels of the active form of alpha-MSH are regulated in mice. Specifically, genetic and biochemical analysis performed by the team, led by Sabrina Diano and Craig Warden, indicated that the protein PRCP is expressed in the hypothalamus and breaks down the active form of alpha-MSH, generating a slightly smaller peptide that does not suppress food intake. Importantly, administration of PRCP inhibitors to both normal and obese mice reduced their food intake. Further, mice lacking PRCP had increased levels of the active form of alpha-MSH in the hypothalamus and were leaner and shorter than normal mice; they also did not get obese when fed a high-fat diet. The authors suggest that these data are the first step in identifying PRCP as a candidate drug target for the treatment of obesity and obesity-related disorders. Although Richard Palmiter, at the University of Washington, Seattle, also raises this intriguing possibility, he cautions that any drug would need to penetrate the brain.
TITLE: Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents https://www.the-jci.org/article.php?id=37209
AUTHOR CONTACT:
Sabrina Diano
Yale University School of Medicine, New Haven, Connecticut, USA.
Craig H. Warden
University of California Davis, Davis, California, USA.
ACCOMPANYING COMMENTARY
TITLE: Reduced levels of neurotransmitter-degrading enzyme PRCP promote obesity https://www.the-jci.org/article.php?id=40001
AUTHOR CONTACT:
Richard D. Palmiter
University of Washington, Seattle, Washington, USA.
Source:
Karen Honey
Journal of Clinical Investigation
Visit our obesity / weight loss / fitness section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/158235.php>
APA
http://www.medicalnewstoday.com/releases/158235.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Nothing New
posted by Fit Because IExercise on 21 Jul 2009 at 10:34 amThis is just another piece of the well-flogged a-MSH/MCH/Melanocortin peptide exploration within the obesity basic research field. I am hopeful for a new medicine for obesity, but modulating these systems has not and will not be the successful approach. To see where this line of research will go, just look at the enormous literature on these peptides, and the negative clinical data.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.







